BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T163258
CREATED:20240704T165308Z
LAST-MODIFIED:20240704T165357Z
UID:39340-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:6th RAS-Targeted Drug Development Summit
DESCRIPTION:The race to target the remaining RAS mutants continues\, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever\, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – making treating patients with RAS mutant cancers beyond NSCLC not just a possibility\, but a reality. \nAs the leading industry-centered forum\, the 6th RAS-Targeted Drug Development Summit 2024 returns to Boston this September and is once again dedicated to every aspect of discovery and development of RAS therapies\, from discovery through to clinical development\, to create effective frontline RAS therapies for cancer and better patient outcomes. \nOver three jam-packed days\, 38+ leading stakeholders will exhibit breakthrough novel data\, latest clinical advancements\, proof-of-concept\, and strategic perspectives\, all armed to improve the standard of care for patients in need. \nThis year’s summit will tackle some of the hottest advances and burning questions in the space\, such as: \n\nTargeting more mutants with RAS(ON) form\, pan-RAS approaches\, and non-canonical targets to combat cancers beyond NSCLC\nDefeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS-directed medicines reach the patient\nShowcasing vaccines\, cell therapies\, monovalent and heterobifunctional modalities with improved selectivity and potency to avoid cancer recurrence\nInvestigating valuable combination approaches utilizing inhibitors of up- and downstream high-value targets such as SOS1\, MEK\, RAF\, and ERK\n\nJoin 200+ of your biopharma and academic peers from Early Discovery\, Translational Oncology\, and Clinical Development at the unrivaled end-to-end forum as we foster critical conversations and navigate cutting-edge treatments – empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment. Join us as we work together to create effective frontline RAS therapies for better patient outcomes. \nTo know more visit: https://ter.li/hosjv6
URL:http://www.pharmajournalist.com/event/6th-ras-targeted-drug-development-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T163258
CREATED:20240815T165629Z
LAST-MODIFIED:20240815T165629Z
UID:39596-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:AI for Pharma & Healthcare Summit
DESCRIPTION:Join us for an exploration of accelerating drug development\, streamlining clinical trials and enhancing supply chain efficiency to elevate patient care across the entire value stream at the AI for Pharma & Healthcare Summit! \nImagine a world where drug discovery moves at unprecedented speeds\, clinical trials are streamlined for efficiency\, and regulatory approvals are faster than ever before. Extend that vision to manufacturing and supply chain processes enhanced by machine learning and predictive analytics to ensure that treatment reaches patients not only quicker but also more safely and reliably. This is the future of pharmaceuticals\, where advanced technology enhances every facet of patient care. \nThe transformative potential of AI is reflected in the sector’s financial outlook: the market for AI in Pharma is expected to grow exponentially\, from $3.05 billion to $18.06 billion by 2029. Yet\, amid the excitement\, a healthy dose of scepticism about the “AI Hype” exists. Pharma professionals understand the power of the technology\, but translating potential into reality requires navigating significant challenges. Pharma IQ’s AI for Pharma & Healthcare Summit aims to address these challenges by going beyond the hype\, presenting real-world AI use cases in drug discovery\, clinical trials and supply chain / manufacturing.
URL:http://www.pharmajournalist.com/event/ai-for-pharma-healthcare-summit/
LOCATION:Amsterdam Marriot Hotel\, Stadhouderskade 12\, Amsterdam\, 1054 ES\, Netherlands
ORGANIZER;CN="IQPC Ltd":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260515T163258
CREATED:20240819T231802Z
LAST-MODIFIED:20240819T231802Z
UID:39620-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:8th MASH Drug Development Summit
DESCRIPTION:With Rezdiffra’s approval\, GLPs moving into the space\, and the wave of promising therapeutics in phrase I-III trials\, MASH therapeutics have seen an unprecedented boom in recent months. \nDon’t miss the 8th MASH Drug Development Summit’s industry-specific curated agenda spanning preclinical\, translational\, clinical and regulatory MASH developments designed to help you to overcome barriers in the development and commercialization of MASH therapies. \nWhat are the top program features to look forward to in 2024? \n\nDelve into preclinical anti-fibrotic developments and their impact on ELF and PRO-C3 biomarkers and how to improve fibrosis replication with BMS\, Pfizer and AstraZeneca\nAccelerate your clinical trial design by optimizing cirrhosis\, MASH and fibrosis targets in trials with AstraZeneca and 89Bio\nExamine how GLP-1s can be leveraged in MASH to combat the disease drivers with Altimmune and Seal Rock Therapeutics\nExplore how the regulatory field is shifting and learn how to navigate regulatory approval with Madrigal and AstraZeneca\nLeverage AI techniques and real-world evidence to integrate data\, harmonize predictions and identify future trends for MASH with Merck and AstraZeneca\n\nFind out more here. \nThis is a conversation you won’t want to miss! Discover pricing and registation information here to discover how you can harness competitive intelligence from 3 days of cutting-edge content to supercharge your MASH therapeutic pipeline.
URL:http://www.pharmajournalist.com/event/8th-mash-drug-development-summit/
LOCATION:Boston Logan Airport Hotel\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR